Abstract
Telomere biology disorders are a complex set of illnesses defined by the presence of very short telomeres. Individuals with classic dyskeratosis congenita have the most severe phenotype, characterized by the triad of nail dystrophy, abnormal skin pigmentation, and oral leukoplakia. More significantly, these individuals are at very high risk of bone marrow failure, cancer, and pulmonary fibrosis. A mutation in one of six different telomere biology genes can be identified in 50–60% of these individuals. DKC1, TERC, TERT, NOP10, and NHP2 encode components of telomerase or a telomerase-associated factor and TINF2, a telomeric protein. Progressively shorter telomeres are inherited from generation to generation in autosomal dominant dyskeratosis congenita, resulting in disease anticipation. Up to 10% of individuals with apparently acquired aplastic anemia or idiopathic pulmonary fibrosis also have short telomeres and mutations in TERC or TERT. Similar findings have been seen in individuals with liver fibrosis or acute myelogenous leukemia. This report reviews basic aspects of telomere biology and telomere length measurement, and the clinical and genetic features of those disorders that constitute our current understanding of the spectrum of illness caused by defects in telomere biology. We also suggest a grouping schema for the telomere disorders.
Similar content being viewed by others
Main
Over the past 5–10 years, it has become increasingly clear that alterations in telomere integrity can directly impact human health. Telomeres are the specialized nucleoprotein structures present at the ends of chromosomes and are comprised of long nucleotide repeats (TTAGGG)n bound by a host of telomere-specific and so-called “accessory” proteins.1,2 The essential function of telomeres derives from the exquisite sensitivity cells have to double-stranded deoxyribonucleic acid (DNA) ends and the robust mechanisms to detect and repair DNA ends created by DNA double-stranded breaks. Telomeres protect the DNA ends present naturally at the termini of linear chromosomes from being acted on as if they were broken ends, thereby inhibiting telomere fusions, illegitimate recombination, and genomic instability.
Because the semiconservative DNA replication machinery is unable to replicate terminal DNA at chromosome ends, telomeric sequence is lost with each round of DNA replication.3 Consequently, telomeres shorten with aging. In peripheral blood leukocytes, the cells most extensively studied, the rate of attrition is greatest during the first year of life.4 Thereafter, telomeres shorten more gradually. When the extent of telomeric DNA loss exceeds a critical threshold, a robust antiproliferative signal is triggered, leading to cellular senescence or apoptosis. Thus, telomere attrition is thought to contribute to aging phenotypes.1
With the 1985 discovery of telomerase,5 the enzyme that extends telomeric nucleotide repeats, there has been rapid progress both in our understanding of basic telomere biology and the connection of telomere biology to human disease. Although the initial focus had been on the relevance of telomere biology to cancer, we now appreciate that there is a spectrum of human disease that originates from inherent defects in telomere length maintenance, making an understanding of telomere biology disorders of importance to a broader spectrum of clinicians. This review will describe the basis of human telomere length variation and inheritance, various methods available to measure telomere length, how a diagnosis of a telomere biology disorder can be established, and, finally, the medical complications associated with short telomeres.
TELOMERASE AND TELOMERE-ASSOCIATED PROTEINS
The elucidation of factors associated with telomerase through basic biology research has been crucial to the identification of genes mutated in telomere biology disorders. A diagram of these proteins is shown in Figure 1. Telomerase consists of two core components, TERT, a reverse transcriptase, and TERC, a ribonucleic acid (RNA) that contains a template for telomere repeat addition.3 The telomerase complex catalyzes the synthesis and extension of terminal telomeric DNA. Telomerase is developmentally regulated, with expression in most human tissues only during the first few weeks of embryogenesis.6 From the neonatal period onward, telomerase activity is largely repressed, except in certain highly proliferative tissues such as skin, intestine, and bone marrow, which are thought to contain stem cell-like subpopulations, and in dividing lymphocytes, ovaries, and testes.6–9 Telomerase is also upregulated in most cancer cells, reflecting the need for telomere maintenance for proliferative potential.7,10
TERT and TERC are sufficient for telomerase reconstitution in vitro, but additional factors are required for telomerase biogenesis, localization, and activity in vivo. Importantly, dyskerin is associated with catalytically active telomerase by TERC and is required for normal TERC levels and telomerase activity in vivo.11 Dyskerin, which is encoded by DKC1, associates with H/ACA box-containing small nucleolar RNAs, including TERC.12 It is also involved in posttranscriptional pseudouridylation and forms a ribonucleoprotein complex with NOP10, NHP2, and GAR1.13,14 These factors are also found in a complex with TERC; they do not mediate its pseudouridylation but instead are involved in the proper stability, regulation, or trafficking of telomerase.15 NAF1, which is exchanged for GAR1 in the dyskerin/NOP10/NHP2 complex, and the ATP-ases pontin and reptin are also required for assembly of the catalytically competent telomerase complex but are not associated with the mature enzyme.16,17 Finally, there is the protein TCAB1, which associates with active telomerase by binding to the CAB box motif of TERC, and is responsible for the localization of telomerase to nuclear Cajal bodies, a critical step for telomere maintenance.18 Given the importance of these factors, we speculate that a mutation in one or more may be identified in human telomere biology disorders in the future.
In addition to telomerase, proteins that bind to telomeric DNA are important for normal telomere maintenance and function. These include shelterin, a six-protein telomere-specific complex, which serves a number of functions including inhibiting the DNA damage response at telomeres, negatively regulating telomerase, and promoting telomere replication and sister telomere cohesion.2 The importance of this complex is underscored by the finding that mutations in one of the shelterin components, TIN2, which is encoded by TINF2, have been found to cause very short telomeres and dyskeratosis congenita (DC, see later).19
TELOMERE LENGTH AND INHERITANCE
Telomere length measurements in a variety of organisms have revealed tremendous variability between species. Individual species, however, maintain their germline telomeres broadly around a defined set point. In humans, telomeres are several kilobases (kb) in length. Telomere length is inversely proportional to age. Although telomere length varies from tissue to tissue, it is correlated within an individual20–22 (unpublished data). This likely reflects the proliferative history of the constituent cells, the level of telomerase activity, and other factors that may lead to telomere attrition. Thus, highly proliferative tissues may exhibit shorter telomere length.
Genetic factors have been shown to impact telomere length in healthy populations, with heritability estimates ranging from 36 to 82%.23–26 Telomere length correlated significantly with paternal but not maternal telomere length in a number of studies, suggesting a possible role for genomic imprinting.27,28 Additionally, inheritance of telomere length follows a polygenic pattern, consistent with a quantitative trait. A number of quantitative trait linkage and genome-wide association studies have been performed to identify genetic factors that modulate telomere length. Several studies have identified single-nucleotide polymorphisms (SNPs) that may contribute to telomere length regulation.29 For example, SNPs were identified in an intron in BICD1, which encodes a protein involved in vacuolar trafficking, and to a region between BRUNOL4 and VPS34, which encode a putative RNA binding protein and a lipid kinase involved in autophagy, respectively.30 The significance of these associations is unclear, although it is notable that vacuolar protein sorting genes, such as VPS34, have been widely implicated in telomere maintenance in a yeast model system.31 Most recently, a SNP was identified in a genome-wide association study of mean telomere length in a region 1.5 kb downstream from TERC.32 Whether the SNP affects TERC expression levels has yet to be evaluated; however, this is an attractive hypothesis as cells are very sensitive to reductions in TERC (see later).
TELOMERE LENGTH MEASUREMENT
Several methods are available in the research setting to determine telomere length in whole cells and DNA preparations (reviewed in Refs. 33 and 34). The current gold standard of telomere length determination is terminal restriction fragment measurement on Southern blots. This method requires several hundred nanograms of high-quality DNA and uses restriction enzymes to digest telomeric DNA. The resultant fragments are run on a Southern blot and the median length determined. Telomere length can be determined on metaphase chromosomes and on fixed or imbedded tissues through the use of telomere-specific probes and fluorescence in situ hybridization (FISH).35 The intensity of the telomeric fluorescent signal is measured relative to another DNA-specific probe. Single telomere length analysis, a polymerase chain reaction-based approach, is useful in understanding telomere length differences between chromosomes.36,37
Quantitative polymerase chain reaction has emerged as a method that is useful in larger epidemiologic studies of telomere length because it is a high-throughput platform.38,39 It requires small amounts of high-quality DNA and determines a ratio of telomere signal to single copy gene signal, which serves as a telomere length surrogate.
Telomere length measurement by automated multicolor flow cytometry combined with FISH (flow-FISH) on white blood cell (WBC) subsets is very useful in understanding telomere length differences in the immune system.35 Unlike other methods, it requires either fresh or cryopreserved blood samples but gives specific measurements on the WBC subset telomere length. Testing of telomere length in WBC subsets using the flow-FISH procedure is currently the only method of determining telomere length that is clinically available. Examples of results from flow-FISH telomere length testing are shown in Figure 2.
The method of telomere length measurement, cell type studied, as well as study design and statistical power, must be considered in the interpretation of data in studies evaluating telomere lengths in individuals with various conditions. For example, there can be considerable interindividual variability in telomere length, even among age-matched subjects. Therefore, a large number of controls are essential to properly interpret data. Many earlier studies reported either the mean telomere length in patients compared with age-matched controls or the difference between the average telomere lengths of patients and controls (deltaTEL). The measurements are useful in understanding the characteristics of a group of individuals but not always applicable to the individual patient. In more recent studies, individual telomere length is plotted against the distribution of age-dependent telomere lengths observed in a large number of “normal” individuals to determine an individual's percentile telomere length (e.g., Fig. 2).35,40
THE TELOMERE BIOLOGY DISORDERS
Abnormalities in telomere biology resulting in clinically significant disease were first recognized in patients with DC.12 Studies of individuals with severe aplastic anemia (SAA), a frequent complication of DC, found that a subset of individuals with SAA had shorter telomeres and mutations in telomere biology genes that overlapped with those that cause DC.41–47 Short telomeres and mutations in the same genes have also been identified in a small percentage of individuals with pulmonary fibrosis,48,49 as well as nonalcoholic liver disease50 and acute myelogenous leukemia (AML).51,52 These disorders represent a broad spectrum of related diseases caused by defective telomere maintenance. This section will describe the clinical presentation, diagnosis, and overlapping features of these related disorders (Box 1).
DYSKERATOSIS CONGENITA
Clinical features
The disorder now known as DC was first described between 1906 and 1910.53 Case reports initially described the diagnostic triad of nail dystrophy, lacy reticular pigmentation of the neck and upper chest, and oral leukoplakia in males. As additional cases were identified, including in females, the presence of bone marrow failure (BMF), cancer, and numerous other medical problems was noted.54,55 Figure 3 shows features of the diagnostic triad. The clinical characteristics may also include abnormal pigmentation changes not restricted to the upper chest and neck, eye abnormalities (epiphora, blepharitis, sparse eyelashes, ectropion, entropion, and trichiasis),56 dental abnormalities (caries and periodontal disease),57 esophageal stenosis, urethral stenosis, avascular necrosis of the femur and/or humerus, osteopenia, pulmonary fibrosis, and liver disease. Patients with DC are at risk of progressive BMF, myelodysplastic syndrome or AML, and solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer).58
Two disorders, Hoyeraal-Hreidarsson syndrome and Revesz syndrome, represent severe variants of DC. Hoyeraal-Hreidarsson syndrome is characterized by many of the DC features listed above plus the presence of cerebellar hypoplasia.59,60 These patients also have significant developmental delay and immunologic abnormalities. Individuals with Revesz syndrome have bilateral exudative retinopathy and intracranial calcifications, in addition to many features of DC.61,62 The determination of very short telomeres and mutations in telomere biology genes in both Hoyeraal-Hreidarsson (DKC1 and TINF2) and Revesz (TINF2) syndromes firmly establishes that these disorders are indeed within the DC spectrum.19,60,63
Inheritance
DC is inherited in X-linked recessive, autosomal dominant, and autosomal recessive forms. Approximately one half of patients with DC have a mutation identified in one of six known genes, DKC1, TERC, TERT, TINF2, NHP2, and NOP10 (Table 1).55,64 The mutations in the X-linked recessive gene, DKC1, were the first link to the role of telomere biology in DC pathogenesis.12,65 Fibroblasts from patients with DKC1 mutations were shown to have very short telomeres.12 This is thought to be due to a decrease in TERC in DKC1 mutant cells, which results in a deficiency in cellular telomerase activity.12
Mutations in TERC or TERT were subsequently identified in the autosomal dominant form of DC.46,47,66 These patients may have classic DC with many complications, whereas others may be less severely affected. Functional analysis of several disease-associated TERC and TERT mutations revealed that they result in short telomeres due to haploinsufficiency of telomerase rather than a dominant negative effect, indicating that telomerase is limiting in normal cells. A small number of severely affected patients have also been shown to have DC due to autosomal recessive inheritance of TERT mutations, which result in significantly decreased levels of telomerase.47,67 Patients with biallelic TERT mutations seem to be more severely affected (i.e., Hoyeraal-Hreidarsson variant) than those with the autosomal dominant TERT mutations.
Homozygosity mapping of consanguineous families with DC identified autosomal recessive inheritance of mutations in NOP10 (one family) or NHP2 (two families) as causative of DC.53,67 The NHP2 and NOP10 proteins associate with dyskerin and GAR1 in the H/ACA small nuclear ribonucleoprotein structures. NHP2 and NOP10 mutations seem to result in reduced levels of TERC, similar to the effects of a DKC1 mutation. Individuals with these mutations have the more severe form of DC, Hoyeraal-Hreidarsson syndrome.
The sixth gene implicated in DC, TINF2, encodes not a component of telomerase but rather a component of the telomeric shelterin complex, TIN2.2,19 In fact, mutations in TINF2 are responsible for a large proportion of autosomal dominant DC.19,68 Patients with TINF2 mutations may have severe forms of DC, including the Revesz syndrome variant but silent carriers (i.e., individuals who have a TINF2 mutation and very short telomeres but lack the clinical phenotype) have also been identified.19 In contrast to the molecular mechanism by which mutations in telomerase components lead to telomere shortening, the mechanism by which TIN2 mutations result in telomere shortening has not yet been identified.
Diagnosis
The ability to diagnose DC has improved during the last 3–4 years, in part, through studies of telomere length in individuals with inherited BMF syndromes (IBMFSs) and other disorders. The diagnosis is quite straightforward in patients who present with the diagnostic triad of dysplastic nails, abnormal skin pigmentation, and oral leukoplakia, with or without additional medical complications. However, the diagnosis is often challenging because the clinical manifestations vary widely in age of onset, even in individuals from the same family. The clinical complications of DC, including the diagnostic triad, can evolve over time. Clinical telomere length testing has helped improve our ability to diagnosis DC.
Measurement of telomere length peripheral WBCs by flow-FISH was found to be both sensitive and specific for identifying patients with DC.40 In that study, telomere length in leukocyte subsets (granulocytes, total lymphocytes, naïve T cells, memory T cells, B cells, and NK cells) was determined by flow-FISH on cells from patients with DC, their relatives, and patients with other IBMFS. Percentiles of telomere length were generated by comparison to a reference group of 400 healthy controls (newborn through 100 years of age).35,40 Values below the 1st percentile for age were considered “very short.” The diagnostic sensitivity and specificity of very short telomeres were >90% in total lymphocytes, naïve T cells, and B cells for the diagnosis of DC in comparison with healthy relatives of patients with DC or non-DC IBMFS patients.40 Rare apparently unaffected relatives with very short telomeres (silent carriers) were later shown to have mutations in the same DC genes as the affected probands.19 Figure 2 shows an example of telomere length results that could be expected from a patient with classic DC compared with patients with SAA and pulmonary fibrosis associated with mutations in TERC or TERT.
A subsequent study from a different laboratory used a modified flow-FISH method, which involved comparison of telomere signal intensity in peripheral blood mononuclear cells with that of an aneuploid (4N) cell line.69 Individual telomere length percentiles were determined based on the age-dependent distribution of telomere length found in a population of 234 healthy controls, ranging from 1 day to 94 years of age. That study found that telomere length was sensitive for DC but not specific. The lack of specificity in that study may have been a consequence, in part, of a smaller number of controls, which resulted in a wider extrapolated 1st percentile interval. The differences between the laboratory and analytic methods of the two studies suggest that the results are not directly comparable.
Most studies to date have evaluated telomere length measurement in total WBCs, which has proven to be a useful surrogate for constitutional telomere length, even when a nonhematopoietic tissue (e.g., lung) is primarily affected. Although tissue-specific telomere factor(s), other than telomerase have yet to be described, it is possible that such factor(s) exists, for which testing of telomere length in WBC may lead to an erroneous conclusion that a particular condition is not a telomere biology disorder.
Genetic anticipation
The penetrance, severity, and time of onset of the clinical features of DC are variable even among family members with the same mutation. The telomere length of paternal, more so than maternal, chromosomes in the zygote is thought to contribute to this variability in healthy individuals.24,27,28,70 Nonetheless, disease anticipation (increasing disease severity and earlier onset with succeeding generations) has been observed in several multigeneration families with autosomal dominant DC.71–74 Mechanistically, disease anticipation has been shown to be associated with progressive telomere shortening and increasing numbers of chromosomes with very short telomeres.71,73 Figure 4 shows the pedigree of a family with autosomal dominant inheritance of a TINF2 mutation. The importance of disease anticipation is that an affected individual may have a phenotypically unaffected but mutation-positive parent, and their siblings may also be at risk. Additionally, carrier offspring may need to be screened for associated illnesses at a younger age than the presentation age of their parents.
Clinical management
The clinical management of DC is complicated due to the highly variable onset and progression of DC manifestations, even between family members.55,75 Individuals may have few physical findings and normal bone marrow function, and others may present at very young ages with the diagnostic triad, early-onset BMF, and other medical problems. Genetic counseling of the patient and family should be incorporated into the management as soon as the diagnosis of DC is considered.75
BMF is often the complication that requires the most intensive management. Hematopoietic stem-cell transplantation (HSCT) is the only curative treatment for BMF and leukemia, but historically, it has had poor long-term efficacy, in part due to treatment-related morbidity and mortality.76–85 Pulmonary fibrosis and hepatic and gastrointestinal complications are frequently reported.78 Recent clinical trials that use nonmyeloablative conditioning regimens and exclude agents known to be associated with severe pulmonary, and hepatic toxicity show promising results but have limited follow-up time.86
If a suitable HSCT donor is not available, androgen therapy may be considered for BMF.75,87 Clinical reports indicate that patients with DC may have an improvement in cytopenias while on androgens, although efficacy data are lacking. Androgens have been shown to affect TERT gene expression and telomerase activity in hematopoietic cells, including TERT mutant cells, providing a potential mechanism of action.88 As with other patients with an IBMFS, patients with DC on androgen therapy need to have careful monitoring for abnormalities in cholesterol, triglycerides, and liver function, and for the development of liver adenomas. It is recommended that BMF patients taking androgens do not use concurrent growth factors, such as granulocyte-colony stimulating factor or erythropoietin, due to reports of splenic peliosis and rupture.89
Individuals with DC are at an 11-fold increased risk of cancer compared with the general population. The risk of certain head and neck cancers, for example, tongue squamous cell cancer, is elevated by about 1000-fold.58 Annual cancer screening by a dermatologist, gynecologist for females, and an otolaryngologist, and biannual dental examinations are important for early detection.75,90 Because the risk of tongue squamous cell cancer is so dramatically elevated in DC, DC should be carefully considered in any individual presenting with this cancer, particularly in young, nonsmoking, nondrinking adults.
APLASTIC ANEMIA
Aplastic anemia is diagnosed based on well-established peripheral blood count and bone marrow cellularity criteria.91 Nonetheless, it is a complex, heterogeneous BMF disorder. It can present at any age and is now often subclassified into inherited and acquired forms, based on underlying etiology. Acquired aplastic anemia may be characterized by the presence of immune-mediated BMF.91 Exposures to putative environmental risk factors, chemicals such as benzene, idiosyncratic reactions to drugs such as chloramphenicol, and certain infections contribute to the etiology of acquired aplastic anemia,91 although in most cases an instigating factor cannot be identified. Immune-mediated T-cell destruction of the bone marrow has been shown both in vitro and in vivo, but the reason for T-cell activation in these patients is not clear. A combination of genetic risk factors, including SNPs in tumor necrosis factor-alpha92,93 and gamma-interferon94 may be contributory. Despite this knowledge, there is no diagnostic test to establish immune-mediated aplastic anemia.
Treatment approaches, long-term prognosis, disease surveillance, and counseling differ substantially for patients with acquired aplastic anemia versus those with an IBMFS. For example, patients with telomere biology disorders do not respond to immunosuppressive therapy for BMF,87 may be at increased risk of HSCT complications, require additional molecular or genetic screening of related HSCT donors, and have an increased risk of certain cancers. Thus, it is crucial to carefully consider a telomere biology disorder as an underlying cause of aplastic anemia. Importantly, BMF may be the first sign of an inherited telomere biology disorder, and, historically, these patients were often initially diagnosed as having acquired aplastic anemia. Today, studies of telomere length by flow-FISH in WBC subsets and mutation analyses of telomere biology genes can be instrumental in differentiating inherited aplastic anemia because of a telomere biology disorder from acquired aplastic anemia and other IBMFS.
Telomere length in patients with acquired aplastic anemia may be relatively shorter than normal, but it is not as short as in patients with telomere biology disorders. Early studies of aplastic anemia suggested that telomeres were shorter than average in mononuclear cells or granulocytes in about one third of patients compared with controls.41–43 Telomerase activity was shown to be upregulated in acquired aplastic anemia, possibly to counteract telomere loss.95 Patients with acquired aplastic anemia may have short telomeres because of the rapid turnover of hematopoietic progenitor cells to compensate for a failing bone marrow.43,96 This effect may be more notable in granulocytes, which turnover rapidly and often have shorter telomeres than mononuclear cells in controls.97
Individuals with apparently acquired aplastic anemia who did not respond to immunosuppression had the shortest telomeres in several studies.41–43 This led to the hypothesis that some individuals with apparently acquired aplastic anemia may have an underlying genetic defect, manifested by short telomeres. This was confirmed by the identification of mutations in TERC44,45 or TERT46,47 in patients with what had been previously diagnosed as having acquired aplastic anemia. The TERC and TERT mutations reported in aplastic anemia do affect enzyme function and, thus, are likely the cause of the short telomeres. Similarly, TINF2 exon 6 mutations were identified in 6 of 106 pediatric anonymous registry patients who underwent unrelated donor HSCT for SAA,98 a cohort for whom immunosuppressive therapy presumably failed. Four of the mutations had been previously reported to be associated with early-onset DC.
These mutations are rare but, taken together, do explain the presence of short telomeres in up to 10% of patients with aplastic anemia. Some of these patients may have a family history of cancer, mild hematopoietic abnormalities, pulmonary fibrosis, or liver disease. Telomere length testing by flow-FISH in WBC subsets is recommended for all patients with aplastic anemia or BMF. This will identify patients with a telomere biology disorder and has major implications for their treatment and long-term outcome, as reviewed earlier in the text.
HEMATOPOIETIC MALIGNANCIES
A number of reports have suggested a pathologic role for telomerase mutations in the development of certain hematologic malignancies. Hypomorphic TERC or TERT mutations were identified in four families in a study of familial myelodysplastic syndrome/AML.51 The mucocutaneous features of DC were absent in these families, although BMF, gastric cancer, and pulmonary fibrosis were reported in some mutation carriers. Constitutional TERT mutations were also reported in cases of sporadic AML,52 although the most frequently associated gene variant, TERT A1062T, was also found in unaffected controls, albeit at a significantly lower frequency (the frequency was increased 3-fold in patients). In a separate study, the hypomorphic A1062T TERT allele was also found at a higher frequency in individuals with chronic lymphocytic lymphoma and diffuse large B-cell lymphoma relative to normal controls.99 Thus, TERT A1062T status is emerging, at the very least, as a risk factor for these particular hematologic malignancies.
IDIOPATHIC PULMONARY FIBROSIS
Idiopathic pulmonary fibrosis (IPF) is a complex disorder characterized by progressive and irreversible lung scarring that ultimately leads to respiratory failure. Most cases are sporadic, although 2–20% seem to be familial with autosomal dominant inheritance and variable penetrance.100 A number of environmental and genetic factors have been implicated, including defective telomere maintenance. In a study of 73 probands from families with IPF, six were found to be heterozygous for mutations in TERT or TERC.48 They also had short telomeres compared with related, wild-type family members as determined in lymphocytes by flow-FISH. Although IPF was the dominant phenotype, one of these probands had other relatives with aplastic anemia. Additional TERT and/or TERC mutations were identified in a separate study of familial and sporadic IPF.49 Again, some family members in these IPF pedigrees had clinical features similar to DC, including anemia, cancer, and osteoporosis/osteopenia. Consistent with a role of defective telomere maintenance in IPF, defective telomere maintenance, pulmonary fibrosis and other pulmonary diseases have been noted in 20% of individuals with DC.101 Patients with DC who undergo HCST are at increased risk of pulmonary complications as well.85 IPF was among the variable clinical phenotypes present in a study of subjects with novel TERC mutations.102 Thus, patients with IPF should be evaluated for germline mutations in TERC and TERT. Those that harbor such a mutation should be considered to be within the DC spectrum and should be managed and counseled in the same way as patients with classical DC.
LIVER DISEASE
Liver disease, peptic ulceration, or enteropathy has also been noted in approximately 7% of individuals with DC.103 The clinicopathologic features of these gastrointestinal manifestations of defective telomere maintenance, however, remain poorly defined. Most information is found in single case reports or small case series. Noncirrhotic portal hypertension104–106 and hepatopulmonary syndrome107 have been reported in individuals with DC. Similar to IPF, liver disease may be the presenting clinical manifestation of a telomere biology disorder. In a study of family members of five unrelated individuals with BMF and TERT or TERC mutations, severe liver disease was found to occur in some mutation carriers independently of BMF or other apparent organ involvement.50 Although the hepatic pathology findings were variable in the seven liver biopsies available for review, combined inflammation and fibrosis, and nodular regeneration were common. Again, as recommended for individuals with IPF, a telomere biology disorder should be considered in individuals with unexplained severe liver disease and family histories with clinical features found in DC.
TELOMERIC REPEAT CONTAINING RNA AND IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME TYPE 1
Once thought to be transcriptionally silent, it is now clear that human telomeres are transcribed to produce telomeric repeat containing RNA (TERRA).108,109 TERRA, which is noncoding RNA, localizes to telomeric foci and has been implicated in the formation of telomeric heterochromatin and telomerase inhibition. Recently, changes in TERRA levels and other aspects of telomere biology were described in immunodeficiency-centromeric instability-facial anomalies syndrome (ICF syndrome type 1, OMIM #242860). ICF type 1 is caused by biallelic mutations in DNA methyltransferase 3b (DNMT3B).110–112 This defect results in abnormal subtelomeric methylation and abnormally short or undetectable telomeres on some chromosome arms.113 Transcription of TERRA is significantly increased in these individuals, possibly due to defects in the telomeric structure caused by aberrant methylation. Thus, ICF type 1 represents the first syndrome in which changes in TERRA have been described. Whether any of the clinical manifestations of ICF type 1 are the result of changes in TERRA remains to be determined.
TELOMERES IN EPIDEMIOLOGY STUDIES
The association of telomere length in surrogate tissues, such as blood or buccal cell DNA, and disease has been evaluated in numerous epidemiologic studies. Several case-control studies have suggested that individuals with cancer may have shorter leukocyte or buccal cell telomere length. These include studies of bladder,114–116 head and neck,116 lung,117 gastric,118,119 and ovarian120 cancer. Case-control and cohort studies of individuals with breast cancer have yielded inconsistent results.121,122 One cohort study of prostate cancer, which evaluated precancer diagnosis specimens, did not find an association between telomere length and prostate cancer.123 Similar null results were found in skin cancer studies.124
Numerous association studies between telomere length and nonmalignant diseases or conditions have been reported as well, including cardiovascular disease,125,126 diabetes,127 obesity,128 and perception of stress.129 A number of these studies have suggested that affected individuals have shorter telomeres than unaffected individuals. Some of these and other studies have evaluated lifestyle factors, such as diet, exercise, and smoking, and telomere length.123,130 Telomere length does seem to be shorter in smokers than nonsmokers, but the effect may be small. Studies of healthy (i.e., normal body mass index, more exercise, higher intakes of fruits and vegetables, and nonsmokers) compared with unhealthy lifestyles have suggested that individually these variables do not significantly contribute to telomere length but that in combination, there is an association between longer telomeres and a healthier lifestyle.123,130
Telomere epidemiology studies seek to find statistically significant associations between relatively small changes in telomere length between cases and controls. This is in contrast to the very short telomeres found in individuals with telomere biology disorders. These combined approaches will advance understanding of the complex mechanisms of telomere length regulation in inherited disorders and common diseases.
SUMMARY AND FUTURE DIRECTIONS
A broad spectrum of clinical phenotypes is now appreciated in telomere biology disorders (Fig. 5 and Box 1). We propose the grouping schema listed in Box 1 in an effort to better define the overlap of telomere biology disorders. DC is the first disease identified to be caused by abnormalities in genes important in telomere biology. It also has the most severe phenotype. Individuals with isolated SAA or IPF may also have a genetic defect in telomere biology. The clinical manifestations of DC develop at highly variable rates, even within family members with the same mutation. Individuals with apparently isolated SAA, IPF, or liver disease warrant consideration aimed at identifying a mutation in a telomere biology gene. Genetic counseling and a detailed family history should be obtained. Individuals with mutations in a telomere biology gene should be counseled for a potential increased risk of cancer because patients with DC have very high cancer rates. The rates of cancer in individuals with isolated SAA or IPF due to TERT or TERC mutations are not known; future studies are needed to better understand cancer incidence in these individuals.
Although mutations in six genes have been shown to cause DC and/or related telomere biology disorders, approximately 40–50% of patients with DC lack a detectable mutation in one of these genes, which suggests that there are others to be identified. DC inheritance follows essentially all inheritance patterns (X-linked recessive, autosomal dominant, and autosomal recessive), but many cases seem to occur sporadically (i.e., with a negative family history). This could be due to new mutations in a family, incomplete disease penetrance, or variable expressivity of the consequences of the mutation. Thus, the absence of a positive family history should not preclude further evaluation of a suspected case.
The complexities of telomere length regulation suggest that there may be many more genes that contribute to DC and related telomere biology disorders. Numerous genes that regulate telomere length are still being identified and further characterized. In addition, there is an increasing body of research literature that supports nontelomeric functions of TERT such as in the Wnt/β-catenin signaling pathway.131 Findings such as these lead to the possibility that certain aspects of human disease associated with TERT mutations or SNPs may be secondary to loss of one or more of these extracurricular activities.
With the availability of telomere length testing and an increasing awareness of the variable presentations, it is likely we will appreciate a greater frequency of telomere biology disorders than previously thought. As laboratory research leads to a greater understanding of the factors that control telomere length, directed therapies for telomere biology disorders may be at hand in the future.
References
Aubert G, Lansdorp PM . Telomeres and aging. Physiol Rev 2008; 88: 557–579.
Palm W, de Lange T . How shelterin protects mammalian telomeres. Annu Rev Genet 2008; 42: 301–334.
Blackburn EH . Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005; 579: 859–862.
Robertson JD, Gale RE, Wynn RF, et al. Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br J Haematol 2000; 109: 272–279.
Greider CW, Blackburn EH . Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405–413.
Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR . Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998; 58: 4168–4172.
Harle-Bachor C, Boukamp P . Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 1996; 93: 6476–6481.
Hiyama K, Hirai Y, Kyoizumi S, et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995; 155: 3711–3715.
Chiu CP, Dragowska W, Kim NW, et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 1996; 14: 239–248.
Shay JW, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787–791.
Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR . Protein composition of catalytically active human telomerase from immortal cells. Science 2007; 315: 1850–1853.
Mitchell JR, Wood E, Collins K . A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999; 402: 551–555.
Hamma T, Ferre-D'Amare AR . The box H/ACA ribonucleoprotein complex: interplay of RNA and protein structures in post-transcriptional RNA modification. J Biol Chem 2010; 285: 805–809.
Meier UT . The many facets of H/ACA ribonucleoproteins. Chromosoma 2005; 114: 1–14.
Trahan C, Martel C, Dragon F . Effects of dyskeratosis congenita mutations in dyskerin, NHP2 and NOP10 on assembly of H/ACA pre-RNPs. Hum Mol Genet 2010; 19: 825–836.
Leulliot N, Godin KS, Hoareau-Aveilla C, et al. The box H/ACA RNP assembly factor Naf1p contains a domain homologous to Gar1p mediating its interaction with Cbf5p. J Mol Biol 2007; 371: 1338–1353.
Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE . Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 2008; 132: 945–957.
Venteicher AS, Abreu EB, Meng Z, et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009; 323: 644–648.
Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP . TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008; 82: 501–509.
Brummendorf TH, Rufer N, Holyoake TL, et al. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann N Y Acad Sci 2001; 938: 293–303.
Graakjaer J, Pascoe L, Der-Sarkissian H, et al. The relative lengths of individual telomeres are defined in the zygote and strictly maintained during life. Aging Cell 2004; 3: 97–102.
Takubo K, Izumiyama-Shimomura N, Honma N, et al. Telomere lengths are characteristic in each human individual. Exp Gerontol 2002; 37: 523–531.
Andrew T, Aviv A, Falchi M, et al. Mapping genetic Loci that determine leukocyte telomere length in a large sample of unselected female sibling pairs. Am J Hum Genet 2006; 78: 480–486.
Njajou OT, Cawthon RM, Damcott CM, et al. Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci USA 2007; 104: 12135–12139.
Slagboom PE, Droog S, Boomsma DI . Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet 1994; 55: 876–882.
Vasa-Nicotera M, Brouilette S, Mangino M, et al. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet 2005; 76: 147–151.
Nordfjall K, Larefalk A, Lindgren P, Holmberg D, Roos G . Telomere length and heredity: indications of paternal inheritance. Proc Natl Acad Sci USA 2005; 102: 16374–16378.
Unryn BM, Cook LS, Riabowol KT . Paternal age is positively linked to telomere length of children. Aging Cell 2005; 4: 97–101.
Mirabello L, Yu K, Kraft P, et al. The association of telomere length and genetic variation in telomere biology genes. Hum Mutat 2010; 31: 1–9.
Mangino M, Richards JB, Soranzo N, et al. A genome-wide association study identifies a novel locus on chromosome 18q12.2 influencing white cell telomere length. J Med Genet 2009; 46: 451–454.
Rog O, Smolikov S, Krauskopf A, Kupiec M . The yeast VPS genes affect telomere length regulation. Curr Genet 2005; 47: 18–28.
Codd V, Mangino M, van der Harst P, et al. Common variants near TERC are associated with mean telomere length. Nat Genet 2010; 42: 197–199.
Baird DM . New developments in telomere length analysis. Exp Gerontol 2005; 40: 363–368.
Lin KW, Yan J . The telomere length dynamic and methods of its assessment. J Cell Mol Med 2005; 9: 977–989.
Baerlocher GM, Lansdorp PM . Telomere length measurements in leukocyte subsets by automated multicolor flow-FISH. Cytometry A 2003; 55: 1–6.
Bendix L, Horn PB, Jensen UB, Rubelj I, Kolvraa S . The load of short telomeres, estimated by a new method, Universal STELA, correlates with number of senescent cells. Aging Cell 2010; 9: 383–397.
Baird DM, Rowson J, Wynford-Thomas D, Kipling D . Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet 2003; 33: 203–207.
Cawthon RM . Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.
Cawthon RM . Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 2009; 37: e21.
Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007; 110: 1439–1447.
Lee JJ, Kook H, Chung IJ, et al. Telomere length changes in patients with aplastic anaemia. Br J Haematol 2001; 112: 1025–1030.
Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC . Progressive telomere shortening in aplastic anemia. Blood 1998; 91: 3582–3592.
Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM . Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001; 97: 895–900.
Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003; 102: 916–918.
Vulliamy T, Marrone A, Dokal I, Mason PJ . Association between aplastic anaemia and mutations in telomerase RNA. Lancet 2002; 359: 2168–2170.
Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005; 352: 1413–1424.
Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A, Dokal I . Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2005; 34: 257–263.
Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356: 1317–1326.
Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104: 7552–7557.
Calado RT, Regal JA, Kleiner DE, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS one 2009; 4: e7926.
Kirwan M, Vulliamy T, Marrone A, et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009; 30: 1567–1573.
Calado RT, Regal JA, Hills M, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA 2009; 106: 1187–1192.
Vulliamy T, Beswick R, Kirwan M, et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci USA 2008; 105: 8073–8078.
Walne AJ, Marrone A, Dokal I . Dyskeratosis congenita: a disorder of defective telomere maintenance?. Int J Hematol 2005; 82: 184–189.
Savage SA, Alter BP . Dyskeratosis congenita. Hematol Oncol Clin North Am 2009; 23: 215–231.
Tsilou ET, Giri N, Weinstein S, Mueller C, Savage SA, Alter BP . Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia and dyskeratosis congenita. Ophthalmology 2010; 117: 615–622.
Atkinson JC, Harvey KE, Domingo DL, et al. Oral and dental phenotype of dyskeratosis congenita. Oral Dis 2008; 14: 419–427.
Alter BP, Giri N, Savage SA, Rosenberg PS . Cancer in dyskeratosis congenita. Blood 2009; 113: 6549–6557.
Hoyeraal HM, Lamvik J, Moe PJ . Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers. Acta Paediatr Scand 1970; 59: 185–191.
Sznajer Y, Baumann C, David A, et al. Further delineation of the congenital form of X-linked dyskeratosis congenita (Hoyeraal-Hreidarsson syndrome). Eur J Pediatr 2003; 162: 863–867.
Revesz T, Fletcher S, al Gazali LI, DeBuse P . Bilateral retinopathy, aplastic anaemia, and central nervous system abnormalities: a new syndrome?. J Med Genet 1992; 29: 673–675.
Riyaz A, Riyaz N, Jayakrishnan MP, Mohamed Shiras PT, Ajith Kumar VT, Ajith BS . Revesz syndrome. Indian J Pediatr 2007; 74: 862–863.
Knight SW, Heiss NS, Vulliamy TJ, et al. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br J Haematol 1999; 107: 335–339.
Vulliamy TJ, Dokal I . Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex. Biochimie 2008; 90: 122–130.
Knight SW, Heiss NS, Vulliamy TJ, et al. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 1999; 65: 50–58.
Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001; 413: 432–435.
Walne AJ, Vulliamy T, Marrone A, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007; 16: 1619–1629.
Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I . TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008; 112: 3594–3600.
Du HY, Pumbo E, Ivanovich J, et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009; 113: 309–316.
Kimura M, Cherkas LF, Kato BS, et al. Offspring's leukocyte telomere length, paternal age, and telomere elongation in sperm. PLoS Genet 2008; 4: e37.
Armanios M, Chen JL, Chang YP, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci USA 2005; 102: 15960–15964.
Goldman F, Bouarich R, Kulkarni S, et al. The effect of TERC haploinsufficiency on the inheritance of telomere length. Proc Natl Acad Sci USA 2005; 102: 17119–17124.
Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I . Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004; 36: 447–449.
Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I . Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006; 107: 2680–2685.
Savage SA, Dokal I, Armanios M, et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer 2009; 53: 520–523.
Berthou C, Devergie A, D'Agay MF, et al. Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1991; 79: 335–336.
Brazzola P, Duval M, Fournet JC, et al. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen. Bone Marrow Transplant 2005; 36: 1103–1105.
de la Fuente J, Dokal I . Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007; 11: 584–594.
Dror Y, Freedman MH, Leaker M, et al. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 847–850.
Gungor T, Corbacioglu S, Storb R, Seger RA . Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 407–410.
Langston AA, Sanders JE, Deeg HJ, et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92: 758–765.
Lau YL, Ha SY, Chan CF, Lee AC, Liang RH, Yuen HL . Bone marrow transplant for dyskeratosis congenita. Br J Haematol 1999; 105: 571.
Nobili B, Rossi G, De Stefano P, et al. Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen. Br J Haematol 2002; 119: 573–574.
Rocha V, Devergie A, Socie G, et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103: 243–248.
Yabe M, Yabe H, Hattori K, et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 389–392.
Dietz AC, Orchard PJ, Baker KS, et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. [published online ahead of print April 12, 2010] Bone Marrow Transplant In press.
Al Rahawan MM, Giri N, Alter BP . Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita. Int J Hematol 2006; 83: 275–276.
Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009; 114: 2236–2243.
Giri N, Pitel PA, Green D, Alter BP . Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. Br J Haematol 2007; 138: 815–817.
Savage SA . Dyskeratosis congenita. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Seattle, Washington: University of Washington, 2009. Available at http://www.genetests.org. Accessed May 17, 2010.
Young NS, Scheinberg P, Calado RT . Aplastic anemia. Curr Opin Hematol 2008; 15: 162–168.
Demeter J, Messer G, Schrezenmeier H . Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. Ann Hematol 2002; 81: 566–569.
Peng J, Liu C, Zhu K, et al. The TNF2 allele is a risk factor to severe aplastic anemia independent of HLA-DR. Hum Immunol 2003; 64: 896–901.
Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol 2004; 126: 682–685.
Shen JB, Tang JY, Zhao JC, et al. Telomerase activity and its correlation with the proliferative potential of bone marrow in aplastic anemia in children. Acta Haematol 2002; 107: 208–212.
Young NS . Pathophysiologic mechanisms in acquired aplastic anemia. Hematology Am Soc Hematol Educ Program 2006; 72–77.
Baerlocher GM, Vulto I, de Jong G, Lansdorp PM . Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 2006; 1: 2365–2376.
Du HY, Mason PJ, Bessler M, Wilson DB . TINF2 mutations in children with severe aplastic anemia. Pediatr Blood Cancer 2009; 52: 687.
Hills M, Lansdorp PM . Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies. Ann N Y Acad Sci 2009; 1176: 178–190.
Wise AL, Schwartz DA . Pulmonary fibrosis, familial. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Seattle, Washington: University of Washington, 2009. Available at http://www.genetests.org. Accessed May 17, 2010.
Marrone A, Walne A, Dokal I . Dyskeratosis congenita: telomerase, telomeres and anticipation. Curr Opin Genet Dev 2005; 15: 249–257.
Marrone A, Sokhal P, Walne A, et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 2007; 92: 1013–1020.
Walne AJ, Dokal I . Telomerase dysfunction and dyskeratosis congenita. Cytotechnology 2004; 45: 13–22.
Abramowsky C, Romero R, Heffron T . Pathology of noncirrhotic portal hypertension: clinicopathologic study in pediatric patients. Pediatr Dev Pathol 2003; 6: 421–426.
Brown KE, Kelly TE, Myers BM . Gastrointestinal involvement in a woman with dyskeratosis congenita. Dig Dis Sci 1993; 38: 181–184.
Kawaguchi K, Sakamaki H, Onozawa Y, Koike M . Dyskeratosis congenita (Zinsser-Cole-Engman syndrome). An autopsy case presenting with rectal carcinoma, non-cirrhotic portal hypertension, and Pneumocystis carinii pneumonia. Virchows Arch A Pathol Anat Histopathol 1990; 417: 247–253.
Renoux MC, Mazars N, Tichit R, Counil F . Cyanosis revealing hepatopulmonary syndrome in a child with dyskeratosis congenita. Pediatr Pulmonol 2010; 45: 99–102.
Deng Z, Norseen J, Wiedmer A, Riethman H, Lieberman PM . TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Mol Cell 2009; 35: 403–413.
Luke B, Lingner J . TERRA. telomeric repeat-containing RNA. EMBO J 2009; 28: 2503–2510.
Hagleitner MM, Lankester A, Maraschio P, et al. Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome). J Med Genet 2008; 45: 93–99.
Hansen RS, Wijmenga C, Luo P, et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci USA 1999; 96: 14412–14417.
Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402: 187–191.
Yehezkel S, Segev Y, Viegas-Pequignot E, Skorecki K, Selig S . Hypomethylation of subtelomeric regions in ICF syndrome is associated with abnormally short telomeres and enhanced transcription from telomeric regions. Hum Mol Genet 2008; 17: 2776–2789.
Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M . Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005; 26: 1263–1271.
McGrath M, Wong JY, Michaud D, Hunter DJ, De V, De I . Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2007; 16: 815–819.
Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003; 95: 1211–1218.
Jang JS, Choi YY, Lee WK, et al. Telomere length and the risk of lung cancer. Cancer Sci 2008; 99: 1385–1389.
Hou L, Savage SA, Blaser MJ, et al. Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18: 3103–3109.
Liu X, Bao G, Huo T, Wang Z, He X, Dong G . Constitutive telomere length and gastric cancer risk: case-control analysis in Chinese Han population. Cancer Sci 2009; 100: 1300–1305.
Mirabello L, Garcia-Closas M, Cawthon R, et al. Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study. Cancer Causes Control 2010; 21: 77–82.
De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ . A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18: 1152–1156.
Svenson U, Nordfjall K, Stegmayr B, et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 2008; 68: 3618–3623.
Mirabello L, Huang WY, Wong JY, et al. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009; 8: 405–413.
Han J, Qureshi AA, Prescott J, et al. A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 2009; 129: 415–421.
Aviv A, Chen W, Gardner JP, et al. Leukocyte telomere dynamics: longitudinal findings among young adults in the Bogalusa Heart Study. Am J Epidemiol 2009; 169: 323–329.
Fitzpatrick AL, Kronmal RA, Gardner JP, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol 2007; 165: 14–21.
Uziel O, Singer JA, Danicek V, et al. Telomere dynamics in arteries and mononuclear cells of diabetic patients: effect of diabetes and of glycemic control. Exp Gerontol 2007; 42: 971–978.
Nordfjall K, Eliasson M, Stegmayr B, Lundin S, Roos G, Nilsson PM . Increased abdominal obesity, adverse psychosocial factors and shorter telomere length in subjects reporting early ageing; the MONICA Northern Sweden Study. Scand J Public Health 2008; 36: 744–752.
Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA 2004; 101: 17312–17315.
Bekaert S, De Meyer T, Rietzschel ER, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell 2007; 6: 639–647.
Choi J, Southworth LK, Sarin KY, et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet 2008; 4: e10.
Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010; 150: 179–188.
Acknowledgements
This work was supported, in part, by the intramural research program of the National Cancer Institute, National Institutes of Health. The authors thank the patients and families who have generously contributed to our understanding of dyskeratosis congenita and telomere biology disorders. They also thank Drs. Blanche Alter and Neelam Giri, National Cancer Institute, for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure: The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Savage, S., Bertuch, A. The genetics and clinical manifestations of telomere biology disorders. Genet Med 12, 753–764 (2010). https://doi.org/10.1097/GIM.0b013e3181f415b5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1097/GIM.0b013e3181f415b5
Keywords
This article is cited by
-
Novel telomerase reverse transcriptase gene mutation in a family with aplastic anaemia
Familial Cancer (2024)
-
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders
Current Hematologic Malignancy Reports (2024)
-
A pan-cancer analysis of Dyskeratosis congenita 1 (DKC1) as a prognostic biomarker
Hereditas (2023)
-
A case report of dyskeratosis congenita caused by a novel TERC mutation
Annals of Hematology (2023)
-
Short telomeres impede germ cell specification by upregulating MAPK and TGFβ signaling
Science China Life Sciences (2023)